Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–60
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Subjects must have a normal creatinine clearance of ≥60 mL/min
Subjects who self-identify their race as Asian
You may not be if
History of any clinically significant medical, neurologic or psychiatric disease as judged by the investigator
History of symptomatic orthostatic hypotension (ie, postural syncope)
Subjects who have received any radiolabelled study drug within 12 months of the Screening Visit.
Subjects who are monitored for radioactivity as part of their occupation
Subjects who have been exposed to radiation levels above background, (eg, throughX-Ray examinations) of \>5mSv in the last year, \>10 mSv over the last 5 years or a cumulative total of \>1mSv per year of life.
Clareo Health | Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration
